Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.

  title={Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.},
  author={William Andrew Yeudall and Catherine A. Vaughan and Hiroshi Miyazaki and Mahesh Ramamoorthy and Miyoung Choi and Christopher G Chapman and Huixin Wang and Elena Black and Anna Bulysheva and Swati Palit Deb and Brad Windle and Sumitra Deb},
  volume={33 2},
The role of dominant transforming p53 in carcinogenesis is poorly understood. Our previous data suggested that aberrant p53 proteins can enhance tumorigenesis and metastasis. Here, we examined potential mechanisms through which gain-of-function (GOF) p53 proteins can induce motility. Cells expressing GOF p53 -R175H, -R273H and -D281G showed enhanced migration, which was reversed by RNA interference (RNAi) or transactivation-deficient mutants. In cells with engineered or endogenous p53 mutants… 

Figures from this paper

p53-R273H upregulates neuropilin-2 to promote cell mobility and tumor metastasis

An important role for DLX2-NRP2 in p53-R273H-induced cell mobility and tumor metastasis is revealed, which leads to upregulation of Neuropilin-2, a multifunctional co-receptor involved in tumor initiation, growth, survival and metastasis.

Mutant p53-Notch1 Signaling Axis Is Involved in Curcumin-Induced Apoptosis of Breast Cancer Cells

  • Yun-Hee BaeJ. H. Ryu S. Bae
  • Biology
    The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology
  • 2013
It is found that curcumin treatment resulted in an induction of apoptosis in MDA-MB-231 cells, together with downregulation of Notch1 and its downstream target, Hes1, and suggest that the targeting of mutant p53 and/or notch1 may be combined with a chemotherapeutic strategy to improve the response of breast cancer cells to curcuming.

Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis

It is suggested that targeting mutant p53, via its reactivation to the wild-type form, may serve as a promising therapeutic strategy for many cancers that harbor mutant p51, and not only will this strategy abrogate Mutant p53 GOF, but it will also restore WT p53 tumor-suppressive functions.

Allele specific gain-of-function activity of p53 mutants in lung cancer cells.

Addiction of lung cancer cells to GOF p53 is promoted by up-regulation of epidermal growth factor receptor through multiple contacts with p53 transactivation domain and promoter

The oncogenic action of GOf p53 in lung cancer is highly dependent on transactivation of the EGFR promoter via a novel transcriptional mechanism involving coordinated interactions of TFs, HATs and GOF p53.

Gain-of-Function Mutants of p53 and Their Role in Tumourigenesis

The p53 gene is a tumour suppressor that is widely mutated in human cancers and recent studies have demonstrated the ability to reduce tumourigenicity in lung cancer cells addicted to their endogenous GOF mutant p53.

Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246

It was found that tumour samples from patients with breast carcinoma carrying mtp53 showed elevated Interferon (IFN) signalling, T umour I nflammation S ignature (TIS) score and infiltration of CD8+ T cells compared to wild type p53 (wtp53) tumours.

Mutant p53-Associated Molecular Mechanisms of ROS Regulation in Cancer Cells

The studies summarized here highlight that GOF mutant p53 isoforms might constitute major targets for selective therapeutic intervention against several types of tumors and that ROS enhancement driven by Mutant p53 might represent an “Achilles heel” of cancer cells, suggesting pro-oxidant drugs as a therapeutic approach for cancer patients bearing the mutant TP53 gene.

A pro-tumorigenic secretory pathway activated by p53 deficiency in lung adenocarcinoma.

It is shown that TP53 loss initiated a pharmacologically actionable secretory process that drove lung adenocarcinoma (LUAD) progression and a small molecule that blocks G55/G45 interactions impaired secretion and reduced TP53-deficient LUAD growth and metastasis.



Tumor-Derived p53 Mutants Induce NF-κB2 Gene Expression

One possible pathway through which mutants of p53 may induce loss of drug sensitivity is via the NF-κB2 pathway, whose overexpression in H1299 cells also leads to chemoresistance.

Tumor-Derived p 53 Mutants Induce NF-B 2 Gene Expression

One possible pathway through which mutants of p53 may induce loss of drug sensitivity is via the NFB2 pathway, whose overexpression in H1299 cells also leads to chemoresistance.

The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis

The identification of ID4 as a transcriptional target of gain-of-function p53 mutants R175H, R273H and R280K highlights the transcriptional axis mutant p53, E2F1 and ID 4 as a still undefined molecular mechanism contributing to tumor neo-angiogenesis.

p53 Attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts.

It is reported that p53 can suppress the production of the chemokine SDF-1 in cultured fibroblasts of both human and mouse origin, suggesting that the ability of p53 to suppress stromal S DF-1 production may be an important mechanism whereby it does its non-cell-autonomous tumor suppressing function.

Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion

It is demonstrated that wild type but not the dominant-negative mutant (V143A) or cancer-specific mutants (R175H or R280K) of p53 repress CXCR4 expression, and proposed that p53 rescue drugs either alone or in combination with chemotherapeutic drugs may be effective in reducing CX CR4-mediated metastasis.

Down-regulation of CXCL5 inhibits squamous carcinogenesis.

It is suggested that CXCL5 production contributes to both enhanced proliferation and invasion of squamous cell carcinomas and that targeting of chemokine pathways may represent a potential therapeutic modality for these lesions.

Modulation of Gene Expression by Tumor-Derived p53 Mutants

It is shown that the increased growth rate imparted by Mutant p53 in H1299 cells requires the transactivation function of mutant p53, and constitutive expression of three common p53 mutants in H 1299 human lung carcinoma cells evokes regulation of a common set of genes, a significant number of which are involved in cell growth regulation.

A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis

Rho family GTPases cooperate with p53 deletion to promote primary mouse embryonic fibroblast cell invasion

It is found that mitogenic activation of Rho family GTPases can cooperate with p53 deficiency to promote primary cell invasion as well as transformation and that multiple signaling components regulated by the Rho proteins are involved in these processes.